Figure 2

Patients with hepatocellular carcinoma and BCLC stage B. Median survival rates in long-acting octreotide [Sandostatin LAR], TACE, multimodal therapy and palliative care were 22.4, 22.0, 35.5 and 2.9 months respectively. Median survival among patients with "active" treatment did not show significant differences (log rank test: P > 0.05).